NCT05869240 - BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors | Biotech Hunter

Enrollment

388

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

August 2, 2025

Study Completion Date

September 1, 2025

Conditions

Solid Tumor

Interventions

DRUG

BPB-101

Subjects will receive an intravenous infusion of BPB-101 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.

Trial Locations (4)

Unknown

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

Sichuan Academy of Medical Sciences-Sichuan Provincial People's Hospital, Chengdu